Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 9/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.31 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654280 | 0.90 | KRAS (0.37) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL18128501 | 0.90 | KRAS (0.37) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25382988 | 0.89 | KRAS (0.36) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25384534 | 0.88 | KRAS (0.37) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL18164041 | 0.86 | KCNH2 (0.47) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25384523 | 0.86 | KRAS (0.36) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25382788 | 0.84 | KRAS (0.35) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25383422 | 0.83 | KRAS (0.35) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL18128480 | 0.81 | KRAS (0.34) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL25386264 | 0.81 | KRAS (0.35) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| EP-3283462-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885CYP3A4 1884/4885CYP2D6 1485/4885 |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885CYP3A4 1884/4885CYP2D6 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.